Conclusion
In a word, SPAG9 is a novel prognostic biomarker for prostate cancer patients.
Methods
Quantitative real-time PCR (qRT-PCR) was adopted to detect the expression of SPAG9 mRNA in prostate cancer tissues. Chi-square was used to evaluate the relationship between SPAG9 expression and the clinical features of prostate cancer patients. Tranwell assay was performed to detect the migration and invasion of prostate cancer cells. Kaplan-Meier curve and Cox regression analysis were used to evaluate the prognostic value of SPAG9 in prostate cancer patients.
Purpose
The present study was designed to explore the expression of sperm associated antigen 9 (SPAG9) in patients with prostate cancer and estimate the correlation between SPAG9 mRNA expression and prognosis of prostate cancer patients. Moreover, we also investigated the role of SPAG9 in migration and invasion of prostate cancer cell lines.
Results
The qRT-PCR results showed that SPAG9 mRNA was highly expressed in prostate cancer tissues than the control group (P<0.05). There was tight relationship between SPAG9 mRNA expression and clinical characteristics such as Gleason score, NED rate and radical prostatectomy (P<0.05). Overexpression of SPAG9 in vitro significantly promoted the migration and invasion of prostate cancer cells (P<0.05). Kaplan-Meier survival analysis demonstrated that patients with high SPAG9 mRNA expression had higher mortality than those with low expression (P<0.001). Both univariate and multivariate analyses revealed that SPAG9 was a prognostic factor for prostate cancer patients (P=0.000, HR=4.878, 95% CI=2.422-9.825).